1
|
Calleris G, Marra G, Massari E, Benfant N, Rajwa P, Ahmed M, Abreu A, Cacciamani G, Ribeiro L, Westhofen T, Tourinho-Barbosa R, Raskin Y, Smith J, Van Der Poel H, Joniau S, Sanchez-Salas R, Kretschmer A, Cathcart P, Gill I, Karnes R, Tilki D, Shariat S, Touijer K, Gontero P. EAU patient selection criteria are predictors of metastasis-free survival in a large contemporary salvage radical prostatectomy patients cohort. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01157-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
Parry M, Sujenthiran A, Nossiter J, Morris M, Berry B, Cathcart P, Clarke N, Payne H, van der Meulen J, Aggarwal A. PD-0768 Treatment-related toxicity of prostate bed versus whole pelvis post-prostatectomy radiation therapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07047-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Parry M, Boyle J, Nossiter J, Morris M, Sujenthiran A, Berry B, Cathcart P, Aggawal A, Van Der Meulen J, Payne H, Clarke N. Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01571-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Fanshawe J, Warren H, Clark C, Kum F, Smekal M, Masiha E, Saada L, Tan C, Deen S, Farooq O, Siddiqi M, Apata-Omisore J, Stroman L, Rusere J, Tasleem A, Nkwam N, Brown C, Elhage O, Cathcart P, Challacombe B, Popert R, Di Benedetto E, Hadjipavlou M. The role of psa density in decision making to perform transperineal prostate biopsy in men with multi-parametric MRI Likert 2 or 3 scores: A retrospective analysis from a multi-centre cancer network study. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01312-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Parry M, Sujenthiran A, Nossiter J, Morris M, Berry B, Cathcart P, Clarke N, Payne H, Van Der Meulen J, Aggawal A. Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01556-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Cathcart P, Smith S, Clayton G. Strengths and limitations of video-conference multidisciplinary management of breast disease during the COVID-19 pandemic. Br J Surg 2021; 108:e20-e21. [PMID: 33640926 PMCID: PMC7799240 DOI: 10.1093/bjs/znaa046] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Accepted: 09/20/2020] [Indexed: 11/18/2022]
Affiliation(s)
- P Cathcart
- Chelmsford Breast Unit, Broomfield Hospital, Court Road, Broomfield, Chelmsford CM1 7ET, UK
| | - S Smith
- Chelmsford Breast Unit, Broomfield Hospital, Court Road, Broomfield, Chelmsford CM1 7ET, UK
| | - G Clayton
- Chelmsford Breast Unit, Broomfield Hospital, Court Road, Broomfield, Chelmsford CM1 7ET, UK
| |
Collapse
|
7
|
Parry M, Cowling T, Sujenthiran A, Nossiter J, Berry B, Cathcart P, Clarke N, Payne H, Aggarwal A, Van der Meulen J. PO-1178: Identifying skeletal-related events for prostate cancer in routinely collected hospital data. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01196-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Parry M, Sujenthiran A, Nossiter J, Cathcart P, Clarke N, Payne H, Aggarwal A. PD-0060: Treatment-related toxicity of hypofractionated radiation therapy for prostate cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00086-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Parry M, Sujenthiran A, Cowling T, Nossiter J, Cathcart P, Clarke N, Payne H, Van der Meulen J, Aggarwal A. PO-1177: Treatment-related toxicity using prostate only vs prostate and pelvic lymph node radiation therapy. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01195-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Sivarajah V, Farquharson B, Mahdi S, Cathcart P, Jeyarajah S. Chronic groin pain following open inguinal hernia repair: has consenting practice improved? Ann R Coll Surg Engl 2020; 103:5-9. [PMID: 32981334 DOI: 10.1308/rcsann.2020.0184] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
INTRODUCTION Chronic groin pain following inguinal hernia surgery is a common and potentially debilitating complication, and yet patients are infrequently informed of this risk. This leaves surgeons open to negligence claims, especially given recent changes to case law, which for the first time highlighted the need for a more patient-centred approach to risk disclosure. We investigated how these changes have influenced our consenting practice with respect to the disclosure of this risk. METHODS We compared how often surgeons discussed the risk of chronic groin pain with adults undergoing elective open unilateral inguinal hernia mesh repairs in 2019 and 2009. The first 50 patients in each of these two years were retrospectively compared. Discussions during the initial consultation and on the day of surgery were assessed by reviewing clinic letters, medical notes and consent forms. FINDINGS The risk of chronic pain was discussed with significantly more patients in 2019 than in 2009 (96% v 54%, p<0.0001). Most of these discussions occurred on the day of surgery (92% v 54%, p<0.0001). Only a few patients had these discussions during their initial consultation (18% v 4%, p<0.025). CONCLUSIONS Discussing the risk of chronic groin pain has improved significantly over the past 10 years. However, these discussions occur mostly on the day of surgery, which gives patients very little time to weigh up the risk. This potentially invalidates the consent they give for surgery. Patients should be given an opportunity to discuss their operative risks in advance of their operation.
Collapse
Affiliation(s)
| | | | - S Mahdi
- East and North Hertfordshire NHS Trust, UK
| | - P Cathcart
- East and North Hertfordshire NHS Trust, UK
| | | |
Collapse
|
11
|
Beckmann K, Singh S, Sandhu P, Santa Olalla A, Dewan K, Cathcart P, Challacombe B, Poppert R, Dasgupta P, Van Hemelrijck M, Elhage O. Is it time to revise active surveillance protocols for men on active surveillance who have negative prostate findings on re-biopsy? EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33626-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
12
|
Berry B, Parry M, Sujenthiran A, Nossiter J, Cowling T, Aggarwal A, Cathcart P, Payne H, Clarke N, Van Der Meulen J. Comparison of complications after transrectal and transperineal prostate biopsy: A national population-based study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34171-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Cathcart P, Moore C, Ahmed H, Leslie T, Arya M, Hindley R, Cahill F, Prendergast A, Coetzee C, Yogeswaran Y, Sooriakumaran P, Emberton M. Functional outcomes from the Robotic surgery After Focal Therapy (RAFT) clinical trial. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33798-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Parry M, Nossiter J, Cowling T, Sujenthiran A, Berry B, Aggarwal A, Cathcart P, Payne H, Clarke N, Skolarus T, Van Der Meulen J. Patient-reported urinary incontinence following radical prostatectomy for prostate cancer and its association with undergoing incontinence surgery: A national population-based study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34038-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Parry MG, Cowling TE, Sujenthiran A, Nossiter J, Berry B, Cathcart P, Aggarwal A, Payne H, van der Meulen J, Clarke NW, Gnanapragasam VJ. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Med 2020; 18:114. [PMID: 32460859 PMCID: PMC7254634 DOI: 10.1186/s12916-020-01588-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 04/07/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high risk). We investigated radical treatment rates according to CPG in men diagnosed with non-metastatic prostate cancer in England between 2014 and 2017. METHODS Patients diagnosed with non-metastatic prostate cancer were identified from the National Prostate Cancer Audit database. Men were risk stratified according to the CPG classification. Risk ratios (RR) were estimated for undergoing radical treatment according to CPG and for receiving radiotherapy for those treated radically. Funnel plots were used to display variation in radical treatment rates across hospitals. RESULTS A total of 61,999 men were included with 10,963 (17.7%) in CPG1 (lowest risk group), 13,588 (21.9%) in CPG2, 9452 (15.2%) in CPG3, 12,831 (20.7%) in CPG4, and 15,165 (24.5%) in CPG5 (highest risk group). The proportion of men receiving radical treatment increased from 11.3% in CPG1 to 78.8% in CGP4, and 73.3% in CPG5. Men in CPG3 were more likely to receive radical treatment than men in CPG2 (66.3% versus 48.4%; adjusted RR 1.44; 95% CI 1.36-1.53; P < 0.001). Radically treated men in CPG3 were also more likely to receive radiotherapy than men in CPG2 (59.2% versus 43.9%; adjusted RR, 1.18; 95% CI 1.10-1.26). Although radical treatment rates were similar in CPG4 and CPG5 (78.8% versus 73.3%; adjusted RR 1.01; 95% CI 0.98-1.04), more men in CPG5 had radiotherapy than men in CPG4 (79.9% versus 59.1%, adjusted RR 1.26; 95% CI 1.12-1.40). CONCLUSIONS The CPG classification distributes men in five risk groups that are about equal in size. It reveals differences in treatment practices in men with intermediate-risk disease (CPG2 and CPG3) and in men with high-risk disease (CPG4 and CPGP5) that are not visible when using the traditional three-tiered risk classification.
Collapse
Affiliation(s)
- M G Parry
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK. .,Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, England.
| | - T E Cowling
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - A Sujenthiran
- Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, England
| | - J Nossiter
- Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, England
| | - B Berry
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.,Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, England
| | - P Cathcart
- Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Aggarwal
- Department of Cancer Epidemiology, Population, and Global Health, King's College London, London, UK.,Department of Radiotherapy, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - H Payne
- Department of Oncology, University College London Hospitals, London, UK
| | - J van der Meulen
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - N W Clarke
- Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.,Department of Urology, Salford Royal NHS Foundation Trust, Salford, UK
| | - V J Gnanapragasam
- Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge, UK.,Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.,Cambridge Urology Translational Research and Clinical Trials Office, Cambridge Biomedical Campus, Cambridge, UK
| |
Collapse
|
16
|
Saifuddin SR, Devlies W, Santaolalla A, Cahill F, George G, Enting D, Rudman S, Cathcart P, Challacombe B, Dasgupta P, Galustian C, Chandra A, Chowdhury S, Gillett C, Van Hemelrijck M. King's Health Partners' Prostate Cancer Biobank (KHP PCaBB). BMC Cancer 2017; 17:784. [PMID: 29166865 PMCID: PMC5700705 DOI: 10.1186/s12885-017-3773-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 11/13/2017] [Indexed: 11/10/2022] Open
Abstract
The KHP PCaBB was established in 2013 and recruits donors from the Urology or Oncology Departments at Guy's Hospital in London (UK). Prostate cancer patients may be approached to give their consent for biobanking at any point in their treatment pathway, which allows residual material from their earlier diagnosis to be transferred and used by the Biobank. Currently, patients are specifically asked to donate samples of blood and surplus prostate tissue as well as permitting access to their clinical and pathological data that continues to be added throughout the course of their disease. Between 2013 and 2015, 549 prostate cancer patients gave their consent to the biobank and, the tissue repository collected 489 blood samples, 120 frozen prostate tissue samples and 1064 formalin fixed paraffin embedded diagnostic blocks.Prostate cancer has become a chronic disease in a large proportion of men, with many men receiving multiple subsequent treatments, and their treatment trajectory often spanning over decades. Therefore, this resource aims to provide an ideal research platform to explore potential variations in treatment response as well as disease markers in the different risk categories for prostate cancer.A recent audit of the KHP PCaBB revealed that between 2013 and 2015, 1796 patients were diagnosed with prostate cancer at King's Health Partners (KHP), out of which 549 (30.6%) gave their consent to KHP PCaBB. Comparisons between demographic and clinical characteristics of patients who had consented compared to the total patient population revealed that the KHP PCaBB is demographically representative of the total prostate cancer patient population seen in Guy's and St Thomas' NHS Foundation Trust (GSTT). We observed no differences in distribution of ethnicity (p = 0.507) and socioeconomic status (p = 0.097). Some differences were observed in clinical characteristics, specifically with treatment type - which differed significantly between the patients who had given consent and total patient population.The KHP PCaBB has thereby amassed a rich data and tissue repository that is largely reflective of both the demographic and clinical diversity within the total prostate cancer patient population seen at KHP, making it an ideal platform for prostate cancer research.
Collapse
Affiliation(s)
- S R Saifuddin
- School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research, King's College London, London, UK
| | - W Devlies
- Faculty of Medicine, KU Leuven, Leuven, Belgium.,Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Santaolalla
- School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research, King's College London, London, UK
| | - F Cahill
- School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research, King's College London, London, UK
| | - G George
- School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research, King's College London, London, UK
| | - D Enting
- Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - S Rudman
- Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - P Cathcart
- Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - B Challacombe
- Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - P Dasgupta
- Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C Galustian
- MRC Centre for Transplantation, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A Chandra
- Pathology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - S Chowdhury
- Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C Gillett
- King's Health Partners Cancer Biobank, Guy's Hospital, London, UK
| | - M Van Hemelrijck
- School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research, King's College London, London, UK.
| |
Collapse
|
17
|
Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton C. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Ann Oncol 2017; 28:2472-2480. [PMID: 28961847 PMCID: PMC5815564 DOI: 10.1093/annonc/mdx355] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm, translational study using targeted multiregion prostate biopsies was carried out to study genomic and T-cell ITH in clinically high-risk PC aiming to identify drivers and potential therapeutic strategies. PATIENTS AND METHODS Forty-nine men with elevated prostate-specific antigen and multiparametric-magnetic resonance imaging detected PC underwent image-guided multiregion transperineal biopsy. Seventy-nine tumour regions from 25 patients with PC underwent sequencing, analysis of mutations, copy number and neoepitopes combined with tumour infiltrating T-cell subset quantification. RESULTS We demonstrated extensive somatic nucleotide variation and somatic copy number alteration heterogeneity in high-risk PC. Overall, the mutational burden was low (0.93/Megabase), but two patients had hypermutation, with loss of mismatch repair (MMR) proteins, MSH2 and MSH6. Somatic copy number alteration burden was higher in patients with metastatic hormone-naive PC (mHNPC) than in those with high-risk localised PC (hrlPC), independent of Gleason grade. Mutations were rarely ubiquitous and mutational frequencies were similar for mHNPC and hrlPC patients. Enrichment of focal 3q26.2 and 3q21.3, regions containing putative metastasis drivers, was seen in mHNPC patients. We found evidence of parallel evolution with three separate clones containing activating mutations of β-catenin in a single patient. We demonstrated extensive intratumoural and intertumoural T-cell heterogeneity and high inflammatory infiltrate in the MMR-deficient (MMRD) patients and the patient with parallel evolution of β-catenin. Analysis of all patients with activating Wnt/β-catenin mutations demonstrated a low CD8+/FOXP3+ ratio, a potential surrogate marker of immune evasion. CONCLUSIONS The PROGENY (PROstate cancer GENomic heterogeneitY) study provides a diagnostic platform suitable for studying tumour ITH. Genetic aberrations in clinically high-risk PC are associated with altered patterns of immune infiltrate in tumours. Activating mutations of Wnt/β-catenin signalling pathway or MMRD could be considered as potential biomarkers for immunomodulation therapies. CLINICAL TRIALS.GOV IDENTIFIER NCT02022371.
Collapse
Affiliation(s)
- M Linch
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| | - G Goh
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Bill Lyons Informatics Centre, UCL Cancer Institute, London, UK
| | - C Hiley
- Division of Cancer Studies, King's College London, London, UK;; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK
| | - Y Shanmugabavan
- Division of Surgery and Interventional Science, University College London, London, UK
| | - N McGranahan
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK
| | - A Rowan
- Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK
| | - Y N S Wong
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Cancer Immunology Unit, UCL Cancer Institute, London, UK;; Research Department of Haematology, UCL Cancer Institute, London, UK
| | - H King
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK
| | - A Furness
- Cancer Immunology Unit, UCL Cancer Institute, London, UK;; Research Department of Haematology, UCL Cancer Institute, London, UK
| | - A Freeman
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK
| | - J Linares
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK
| | - A Akarca
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK
| | - J Herrero
- Bill Lyons Informatics Centre, UCL Cancer Institute, London, UK
| | - R Rosenthal
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Bill Lyons Informatics Centre, UCL Cancer Institute, London, UK
| | | | | | - G A Wilson
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK
| | - N J Birkbak
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK
| | - R Mitter
- Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK
| | - S Dentro
- Cancer Genomics Laboratory, The Francis Crick Institute, London, UK;; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK
| | - P Cathcart
- The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, London, UK
| | - M Arya
- Division of Surgery and Interventional Science, University College London, London, UK;; Department of Urology, UCLH NHS Foundation Trust, London, UK
| | - E Johnston
- Centre for Medical Imaging, Universtiy College London, London, UK
| | - R Scott
- Division of Surgery and Interventional Science, University College London, London, UK
| | - M Hung
- Division of Surgery and Interventional Science, University College London, London, UK
| | - M Emberton
- Division of Surgery and Interventional Science, University College London, London, UK;; Department of Urology, UCLH NHS Foundation Trust, London, UK
| | - G Attard
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK;; Department of Medical Oncology, Royal Marsden Hospital, London, UK
| | - Z Szallasi
- Centre for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark;; Computational Health Informatics Program (CHIP), Harvard Medical School, Boston, USA;; MTA-SE-NAP Brain Metastasis Research Group, Semmelweis University, Budapest, Hungary
| | - S Punwani
- Centre for Medical Imaging, Universtiy College London, London, UK
| | - S A Quezada
- Cancer Immunology Unit, UCL Cancer Institute, London, UK;; Research Department of Haematology, UCL Cancer Institute, London, UK
| | - T Marafioti
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK
| | - M Gerlinger
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK;; Department of Medical Oncology, Royal Marsden Hospital, London, UK
| | - H U Ahmed
- Division of Surgery and Interventional Science, University College London, London, UK;; Division of Surgery, Department of Surgery and Cancer, Imperial College London, UK;; Department of Urology, Imperial College Healthcare NHS Trust, London, UK.
| | - C Swanton
- Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London, UK;; Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK;; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK;.
| |
Collapse
|
18
|
Gnanapragasam VJ, Hori S, Johnston T, Smith D, Muir K, Alonzi R, Winkler M, Warren A, Staffurth J, Khoo V, Tree A, Macneill A, McMenemin R, Mason M, Cathcart P, de Souza N, Sooriakumaran P, Weston R, Wylie J, Hall E, Lane A, Cross W, Syndikus I, Koupparis A. Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup. Journal of Clinical Urology 2016. [DOI: 10.1177/2051415816651362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The management of high-risk prostate cancer has become increasingly sophisticated, with refinements in radical therapy and the inclusion of adjuvant local and systemic therapies. Despite this, high-risk prostate cancer continues to have significant treatment failure rates, with progression to metastasis, castrate resistance and ultimately disease-specific death. In an effort to discuss the challenges in this field, the UK National Clinical Research Institute’s Prostate Cancer Clinical Studies localised subgroup convened a multidisciplinary national meeting in the autumn of 2014. The remit of the meeting was to debate and reach a consensus on the key clinical and research challenges in high-risk prostate cancer and to identify themes that the UK would be best placed to pursue to help improve outcomes. This report presents the outcome of those discussions and the key recommendations for future research in this highly heterogeneous disease entity.
Collapse
Affiliation(s)
| | - S Hori
- Academic Urology Group, University of Cambridge, UK
| | - T Johnston
- Academic Urology Group, University of Cambridge, UK
| | - D Smith
- Prostate Cancer Support Association, UK
| | - K Muir
- Institute of Public Health, University of Manchester, UK
| | - R Alonzi
- Department of Clinical Oncology, Mount Vernon Cancer Centre, UK
| | - M Winkler
- Department of Urology, Charing Cross Hospital, UK
| | - A Warren
- Department of Pathology, Addenbrookes Hospital, UK
| | - J Staffurth
- Institute of Cancer and Genetics, Cardiff University, UK
| | - V Khoo
- Department of Clinical Oncology, Royal Marsden Hospital, UK
| | - A Tree
- Department of Clinical Oncology, Royal Marsden Hospital, UK
| | - A Macneill
- Department of Urology, Western General Hospital, NHS Lothian, UK
| | | | - M Mason
- Institute of Cancer and Genetics, Cardiff University, UK
| | - P Cathcart
- Department of Urology, UCL Hospitals, UK
| | | | | | - R Weston
- Department of Urology, Royal Liverpool University Hospital, UK
| | - J Wylie
- Department of Oncology, Christie Hospital, UK
| | - E Hall
- Clinical Trials and Statistics Unit; Institute of Cancer Research, UK
| | - A Lane
- Department of Social Medicine, University of Bristol, UK
| | - W Cross
- Department of Urology, St. James’s University Hospital, UK
| | - I Syndikus
- Radiotherapy Department, Clatterbridge Cancer Centre, UK
| | - A Koupparis
- Department of Urology, Bristol Urological Institute, UK
| | | |
Collapse
|
19
|
Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, Cook G, Cahill D, Cahill F, Olalla AS, George G, Rudman S, van Hemelrijck M. Metformin and longevity (METAL): A window of opportunity study investigating the biological effects of metformin in localised prostate cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Aggarwal A, Nossiter J, Cathcart P, van der Meulen J, Rashbass J, Clarke N, Payne H. Organisation of Prostate Cancer Services in the English National Health Service. Clin Oncol (R Coll Radiol) 2016; 28:482-489. [DOI: 10.1016/j.clon.2016.02.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Revised: 01/18/2016] [Accepted: 01/19/2016] [Indexed: 11/28/2022]
|
21
|
Khoo CCK, Mahmalji W, Tay A, Shabbir M, Cathcart P. Emergency management of foreskin/urethral superglue injuries. Int Urol Nephrol 2016; 48:225-6. [PMID: 26725069 DOI: 10.1007/s11255-015-1166-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Accepted: 10/28/2015] [Indexed: 11/26/2022]
Affiliation(s)
- C C K Khoo
- Department of Urology, The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
| | - W Mahmalji
- Department of Urology, The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK
| | - A Tay
- Department of Urology, The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK
| | - M Shabbir
- Department of Urology, The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK
| | - P Cathcart
- Department of Urology, The Urology Centre, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK
| |
Collapse
|
22
|
Michel C, Freeman A, Jameson C, Waddington W, Cathcart P. Détection des marges chirurgicales en imagerie par Cerenkov Luminescence au cours des prostatectomies radicales cœliosocpiques robot-assistées – résultats initiaux de l’étude PRIME. Prog Urol 2015; 25:796-7. [DOI: 10.1016/j.purol.2015.08.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
23
|
Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol 2015; 26:848-864. [PMID: 25403590 DOI: 10.1093/annonc/mdu525] [Citation(s) in RCA: 127] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 11/04/2014] [Indexed: 02/11/2024] Open
Abstract
BACKGROUND Despite the extensive development of risk prediction models to aid patient decision-making on prostate screening, it is unknown whether these models could improve predictive accuracy of PSA testing to detect prostate cancer (PCa). The objective of this study was to perform a systematic review to identify PCa risk models and to assess the model's performance to predict PCa by conducting a meta-analysis. DESIGN A systematic literature search of Medline was conducted to identify PCa predictive risk models that used at least two variables, of which one of the variables was prostate-specific antigen (PSA) level. Model performance (discrimination and calibration) was assessed. Prediction models validated in ≥5 study populations and reported area under the curve (AUC) for prediction of any or clinically significant PCa were eligible for meta-analysis. Summary AUC and 95% CIs were calculated using a random-effects model. RESULTS The systematic review identified 127 unique PCa prediction models; however, only six models met study criteria for meta-analysis for predicting any PCa: Prostataclass, Finne, Karakiewcz, Prostate Cancer Prevention Trial (PCPT), Chun, and the European Randomized Study of Screening for Prostate Cancer Risk Calculator 3 (ERSPC RC3). Summary AUC estimates show that PCPT does not differ from PSA testing (0.66) despite performing better in studies validating both PSA and PCPT. Predictive accuracy to discriminate PCa increases with Finne (AUC = 0.74), Karakiewcz (AUC = 0.74), Chun (AUC = 0.76) and ERSPC RC3 and Prostataclass have the highest discriminative value (AUC = 0.79), which is equivalent to doubling the sensitivity of PSA testing (44% versus 21%) without loss of specificity. The discriminative accuracy of PCPT to detect clinically significant PCa was AUC = 0.71. Calibration measures of the models were poorly reported. CONCLUSIONS Risk prediction models improve the predictive accuracy of PSA testing to detect PCa. Future developments in the use of PCa risk models should evaluate its clinical effectiveness in practice.
Collapse
Affiliation(s)
- K S Louie
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
| | - A Seigneurin
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Joseph Fourier University-Grenoble 1, CNRS, TIMC-IMAG UMR 5525, Grenoble; Medical Evaluation Unit, Grenoble University Hospital, Grenoble, France
| | - P Cathcart
- Department of Urology, University College Hospital London and St Bartholomew's Hospital London and Centre for Experimental Cancer Medicine, Bart's Cancer Institute, London; The Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK
| | - P Sasieni
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| |
Collapse
|
24
|
Louie KS, Seigneurin A, Cathcart P, Sasieni P. Reply to the letter to the editor 'Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis' by Louie et al. Ann Oncol 2015; 26:1031-1032. [PMID: 25672895 DOI: 10.1093/annonc/mdv068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2024] Open
Affiliation(s)
- K S Louie
- Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK;.
| | - A Seigneurin
- Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK;; Université Joseph Fourier Grenoble 1, CNRS, TIMC-IMAG UMR 5525, Grenoble;; Unité d'évaluation Médicale, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | - P Cathcart
- Department of Urology, University College Hospital London & St Bartholomew's Hospital London & Centre for Experimental Cancer Medicine, Bart's Cancer Institute, London, UK
| | - P Sasieni
- Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| |
Collapse
|
25
|
Cathcart P, Hettiarachchi T, Sathesh-Kumar T. A cost effective approach to laparoscopic transabdominal preperitoneal hernia repair. Ann R Coll Surg Engl 2014; 96:551-2. [PMID: 25245743 DOI: 10.1308/rcsann.2014.96.7.551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- P Cathcart
- Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, UK
| | | | | |
Collapse
|
26
|
Aggarwal A, Cathcart P, Payne H, Neal D, Rashbass J, Nossiter J, van der Meulen J. The National Prostate Cancer Audit — Introducing a New Generation of Cancer Audit. Clin Oncol (R Coll Radiol) 2014; 26:90-3. [DOI: 10.1016/j.clon.2013.10.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Revised: 09/09/2013] [Accepted: 09/24/2013] [Indexed: 10/26/2022]
|
27
|
Klimach SG, Gollop ND, Ellis J, Cathcart P. How does subintimal angioplasty compare to transluminal angioplasty for the treatment of femoral occlusive disease? Int J Surg 2014; 12:361-4. [PMID: 24480239 DOI: 10.1016/j.ijsu.2014.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Revised: 01/01/2014] [Accepted: 01/13/2014] [Indexed: 10/25/2022]
Abstract
A best evidence topic in surgery was written according to a structured protocol. The question addressed how subintimal angioplasty (SIA) compares to transluminal angioplasty (TA) for the treatment of femoral occlusive disease. One hundred and thirty two papers were found using the reported search; the 5 which represented the best evidence to answer the question are discussed. The evidence on this subject is limited; there are no randomised controlled trials (RCTs) comparing SIA to TA for pathologically equivalent lesions. However SIA remains a safe and effective alternative to surgical bypass grafting when TA cannot be performed.
Collapse
Affiliation(s)
- S G Klimach
- Brighton and Sussex Medical School, University of Sussex, Brighton, UK
| | - N D Gollop
- The Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK.
| | - J Ellis
- The Queen Elizabeth Hospital, King's Lynn, Norfolk, UK
| | - P Cathcart
- The Queen Elizabeth Hospital, King's Lynn, Norfolk, UK
| |
Collapse
|
28
|
Ahmed H, Cathcart P, McCartan N, Kirkham A, Allen C, Freeman A, Emberton M. 225 FOCAL SALVAGE THERAPY COMPARED TO WHOLE-GLAND SALVAGE: A FEASIBILITY STUDY. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/s1569-9056(11)60225-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Cathcart P, Nuttall M, van der Meulen J, Emberton M, Kenny SE. Trends in paediatric circumcision and its complications in England between 1997 and 2003. Br J Surg 2006; 93:885-90. [PMID: 16673355 DOI: 10.1002/bjs.5369] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND It has been suggested that too many English boys undergo circumcision. This report describes how circumcision rates have changed in England between 1997 and 2003, including data on complication rates and on how age, medical indication and surgical specialty affect postoperative haemorrhage rates. METHODS Data were extracted from the Hospital Episode Statistics database of admissions to National Health Service hospitals in England. Patients were included in the study if an Office of Population Censuses and Surveys version 4 code for circumcision was present in any of the operative procedure fields of the database; 75 868 boys below 15 years of age were included in the study. RESULTS Circumcision rates declined by about 20 per cent, from 2.6 per 1000 boys per year in 1997 to 2.1 in 2003. Between 2000 and 2003, circumcision rates remained static at 2.1 per 1000 boys per year. Circumcision rates fell by 31.2 per cent for boys aged 0-4 years, 9.3 per cent for boys aged 5-9 years and increased by 7.7 per cent in boys aged 10-14 years; 90.2 per cent of circumcisions were done for phimosis and 1.2 per cent of boys experienced a complication. CONCLUSION Circumcision rates in England continued to fall up until 2000, particularly in those aged under 5 years, in whom pathological phimosis is rare. The circumcision rate remains five times higher than the reported incidence of Phimosis.
Collapse
Affiliation(s)
- P Cathcart
- Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK
| | | | | | | | | |
Collapse
|
30
|
|
31
|
Abstract
This practice parameter, developed by the Practice Parameters and Outcomes Measurement Committee of the American Society of Clinical Pathologists (ASCP), is a guideline for the development of reasonable stat lists. Stat testing lists vary according to practice setting. Furthermore, although stat lists exist, extenuating clinical circumstances may warrant performing a test stat that is otherwise considered routine. Successful development of a stat testing list requires organizations to take an interdisciplinary approach, focusing on clinical and operational considerations of both the care provider and the clinical laboratory.
Collapse
Affiliation(s)
- L Hilborne
- Department of Pathology, UCLA School of Medicine, Los Angeles, California, USA
| | | | | |
Collapse
|